Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer —A definite conclusion?
This review on the use of anti-angiogenic agents in second-line treatment of metastatic colorectal cancer (mCRC) has carefully examined a large amount of data coming from more than 20 randomized studies with a pertinent analysis method [1]. The second part of the work presents the results of a meta-analysis of published data and provides new insight on this pragmatic question that we all face in our daily clinical practice.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: M. Ducreux, P. Ă–sterlund, J.P. Pignon Tags: Commentary Source Type: research